Not Disclosed | Symmetry Surgical (logo), a portfolio company of RoundTable Healthcare Partners (logo), has been acquired by Aspen Surgical Products (logo), a portfolio company of Audax Group | October 2022

William Blair acted as lead financial advisor to Symmetry Surgical (Symmetry), a portfolio company of RoundTable Healthcare Partners (RoundTable), in connection with its sale to Aspen Surgical Products (Aspen), a portfolio company of Audax Group. The transaction signed on September 7, 2022 and closed on October 25, 2022.

About the Companies

Based in Nashville, TN, with additional operations in Louisville, KY, Tuttlingen, Germany and Melbourne, Australia, Symmetry is a leading provider of high-quality surgical and specialty instrumentation, electrosurgery products, and minimally invasive surgical devices. Symmetry maintains a rich legacy of trusted brands, innovation and customer service, supporting all surgical specialties and sites of care.

Founded in 2001, RoundTable is an operating-oriented private equity firm focused exclusively on the healthcare industry. Based in Lake Forest, IL, the firm has made 29 platform investments since inception and supported those investments with more than 70 add-on transactions. RoundTable is currently investing out of its $800 million, sixth private equity fund.

Aspen is a leading provider of branded and private label disposable surgical products focused on improving patient and healthcare provider safety and efficiency in the hospital and surgery center environment. Founded in 1999, Aspen’s vertically integrated facilities across North America design, manufacture and deliver high-quality and high-demand products to healthcare facilities around the world.

Founded in 1999, Audax Group is a leading alternative investment manager that has raised more than $30 billion in capital across its private equity and private debt businesses. Audax Private Equity has invested over $9 billion in more than 150 platforms and over 1,100 add-on companies and is currently investing in add-ons out of its $3.5 billion, sixth private equity fund.

Learn more about our medical technology investment banking expertise.